BRIM-3 trial in melanoma: prognostic factors of overall survival and the issue of salvage therapies
Tumor-infiltrating lymphocytes and survival in melanoma
What to do with BRAF-mutant melanoma patients who have a poor prognosis?
Immunotherapy and targeted therapies for melanoma
Immunotherapy for lung cancer and trial of ramucirumab plus pembrolizumab